Contact
Please use this form to send email to PR contact of this press release:
Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
TO:
Please use this form to send email to PR contact of this press release:
Spark Therapeutics Receives Rare Pediatric Disease Designation for Investigational LUXTURNA™ (voretigene neparvovec) from FDA
TO: